Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28311749 | 0.77 | CYP2C9 (0.41) | NPSR1KMT2AMEN1CYP2C9CYP2C19 | |
| SCHEMBL13460530 | 0.74 | CYP2C19 (0.39) | NPSR1KMT2ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL17927203 | 0.74 | CYP2C19 (0.39) | NPSR1KMT2ACYP2C9CYP2C19CYP1A2 | |
| SCHEMBL1291194 | 0.72 | KDM4E (0.39) | NPSR1KMT2AMEN1CYP2C9CYP2C19 | |
| SCHEMBL10839660 | 0.71 | KMT2A (0.41) | KMT2AMEN1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL10838108 | 0.71 | KMT2A (0.41) | KMT2AMEN1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL5618223 | 0.71 | KMT2A (0.41) | KMT2AMEN1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL28173175 | 0.70 | CYP2C19 (0.37) | NPSR1KMT2AMEN1CYP2C9CYP2C19 | |
| SCHEMBL15786468 | 0.69 | TAAR1 (0.47) | NPSR1KMT2ACYP2C19ALDH1A1MAPT | |
| SCHEMBL13879187 | 0.69 | TSHR (0.39) | NPSR1PTPN1ALDH1A1TSHRKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112199-A1 | Asymmetric aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112199-A1 | Asymmetric aldol additions using bifunctional cinchona-alkaloid-based catalysts | AKR1C2, AKR1A1, AKR1B1 | NPSR1 2523/4885KMT2A 622/4885MEN1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.